Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resveratrol - Sirtris

Drug Profile

Resveratrol - Sirtris

Alternative Names: 184072; GSK184072; SRT 501

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirtris Pharmaceuticals
  • Developer GlaxoSmithKline; Sirtris
  • Class Antidementias; Antineoplastics; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Antioxidants; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - MELAS syndrome

Highest Development Phases

  • Discontinued Cancer metastases; Colorectal cancer; MELAS syndrome; Multiple myeloma; Multiple sclerosis; Optic neuritis; Type 2 diabetes mellitus

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in Denmark (PO)
  • 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top